ARTA
LGND icon

A.R.T. Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

A.R.T. Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-22,759
Closed -$1.69M – 920
2016
Q2 		$1.69M Buy
+22,759
New +$1.69M 0.08% 366
2015
Q3 		– Sell
-58,420
Closed -$3.68M – 1481
2015
Q2 		$3.68M Buy
+58,420
New +$3.19M 0.12% 235
2015
Q1 		– Sell
-71,470
Closed -$2.37M – 1562
2014
Q4 		$2.37M Sell
71,470
-35,865
-33% -$1.17M 0.09% 333
2014
Q3 		$3.15M Buy
107,335
+48,335
+82% +$1.6M 0.15% 199
2014
Q2 		$2.29M Buy
+59,000
New +$2.39M 0.12% 241
2013
Q4 		– Sell
-68,729
Closed -$1.85M – 1394
2013
Q3 		$1.85M Sell
68,729
-37,141
-35% -$1.04M 0.1% 292
2013
Q2 		$2.47M Buy
+105,870
New +$1.9M 0.08% 339

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

A.R.T. Advisors's LGND Position: Q3 2016 in Review

A.R.T. Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 22,759 shares — an estimated $1.69M sold.

A.R.T. Advisors first reported a position in LGND in Q2 2013 and held it in 7 quarters. The position peaked at $3.68M in Q2 2015. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • A.R.T. Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • A.R.T. Advisors sold 22,759 Ligand Pharmaceuticals shares in Q3 2016, an estimated $1.69M.
  • A.R.T. Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • A.R.T. Advisors's Ligand Pharmaceuticals position peaked at $3.68M in Q2 2015.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on A.R.T. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.